Therapeutic Antibodies

Monoclonal antibody
#Dermatology #Monoclonal antibodies #Orphan drugs #Sanofi

Biologic achieves improvements in bullous pemphigoid

A Dupixent (dupilumab) pivotal study (ADEPT) in bullous pemphigoid (BP) has met the primary and all key secondary endpoints evaluating its investigational use in adults with moderate-to-severe disease. In the study, five times more Dupixent patients achieved sustained disease remission compared to those on placebo. Read More

#News

#Drug discovery #Therapeutic Antibodies

Webinar: Next-gen antibody discovery: Leveraging DNA immunisation and single B-cell cloning for high-affinity & specificity rabbit mAbs – FUJIFILM – 09.09.2024 DDW

Watch this engaging and informative webinar on Fujifilm Wako’s groundbreaking advancements in rabbit monoclonal antibody discovery. Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with its proprietary single B-cell cloning technique, paving the way… Read More

#Webinars

#Cancer vaccine #Clinical trials #Lung cancer #Monoclonal antibodies #Obesity #Schizophrenia

New DDW Highlights podcast: 2 September 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the launch of an international clinical trial investigating BioNTech’s mRNA lung cancer vaccine… Read More

#News

#Cancer vaccine #Clinical trials #Lung cancer #Monoclonal antibodies #Obesity #Schizophrenia

New DDW Highlights vodcast: 2 September 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   With the launch of an… Read More

#News

Antibodies
#Antibodies #Antibody #Antibody discovery workflow #Drug discovery #Webinar

One week to go: Discover next-generation antibody production

Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Join DDW on 9 September 3PM BST to find out how Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with their proprietary single B-cell cloning technique, paving the way for… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

#Cancer vaccine #Clinical trials #Lung cancer #Monoclonal antibodies #Obesity #Schizophrenia

This week in drug discovery (26-30 August) 

News round-up for 26-30 August by DDW Senior Digital Content Editor Diana Spencer. With the launch of an international clinical trial investigating BioNTech’s mRNA lung cancer vaccine announced this week, our news highlights focus on clinical trials, including studies of a monoclonal antibody and small molecule GLP-1 agonist for… Read More

#News

Monoclonal antibodies
#GLP-1 #Monoclonal antibodies #Obesity #Phase II trial #Skye Bioscience #Weight loss

Monoclonal antibody CB1 inhibitor for obesity enters Phase II trials

Skye Bioscience has started screening patients for a Phase II clinical trial (CBeyond) of its novel peripheral CB1 inhibitor, nimacimab, a negative allosteric modulating antibody. The study will assess the ability of nimacimab as a next-generation weight loss therapeutic to safely and effectively reduce weight in… Read More

#Editor's Choice #News

Antibodies
#Antibodies #Antibody #Antibody discovery workflow #Drug discovery #Webinar

Learn how to produce high-affinity & specificity rabbit mAbs

Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Join DDW on 9 September 3PM BST to find out how Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with their proprietary single B-cell cloning technique, paving the way for… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

FDA headquarters
#Bispecific Antibodies #FDA #Oncology #Orphan drugs #Phanes Therapeutics

Neuroendocrine carcinoma drug granted orphan status

Phanes Therapeutics' PT217 has received orphan drug designation (ODD) for neuroendocrine carcinoma (NEC) from the US Food and Drug Administration (FDA). PT217 is a first-in-class bispecific antibody targeting delta-like ligand 3 (DLL3) and cluster of differentiation 47 (CD47) being developed for patients with NEC. NEC is known to be the… Read More

#Cancer Research #News #Regulatory

Antibodies
#Antibodies #Antibody #Antibody discovery workflow #Drug discovery #Webinar

Next-gen antibody discovery: Leveraging DNA immunisation

Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Join DDW on 9 September 3PM BST to find out how Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with their proprietary single B-cell cloning technique, paving the way for… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Gastric cancer
#Astellas Pharma #Gene mutation #MHRA #Monoclonal antibodies #Oncology

First claudin 18.2 biomarker targeted therapy licensed in Britain

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has licensed Astellas’ Vyloy (zolbetuximab), an anti-claudin 18.2 (CLDN18.2) monoclonal antibody. It is licensed in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric… Read More

#News #Regulatory

Antibodies
#Antibodies #Antibody #Antibody discovery workflow #Drug discovery #Webinar

New webinar: Next-generation antibody discovery

Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Join DDW on 9 September 3PM BST to find out how Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with their proprietary single B-cell cloning technique, paving the way for… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

CT scans of the brain
#Alzheimer's #Antibodies #Biogen #Biologics #Eisai #Neurodegenerative disorders

Data demonstrate long-term effect of lecanemab in early Alzheimer’s

Lecanemab-irmb (Leqembi), an anti-amyloid beta (Aβ) protofibril antibody, continues to show benefit for early Alzheimer’s disease (AD) patients over three years, according to new trial results. Eisai and Biogen shared the latest findings at the Alzheimer’s Association International Conference (AAIC) 2024, held in Philadelphia. Read More

#News

Biologic drugs
#Asthma #Biologics #Eczema #Glen Clova Scientific #Start-ups #University of Dundee

Improving the standard of biological drugs

DDW Editor Reece Armstrong speaks to Dr Steven Powell, co-founder of Glen Clova Scientific (GCS), about the company’s approach of using virus-like particles (VLPs) to treat conditions such as eczema and asthma, and what the current market looks like for this therapy area. Spun-out of the Univeristy of Dundee in… Read More

#Exclusive Content #Start-up Zone

Bispecific antibodies
#Bispecific Antibodies #Dren Bio #Novartis #Oncology #Partnership

Novartis and Dren Bio partner on bispecific antibodies for cancer

Dren Bio and Novartis Pharma have entered a strategic collaboration focused on the discovery and development of therapeutic bispecific antibodies for cancer. Under the terms of the agreement, Dren Bio will receive a total upfront consideration of $150 million from Novartis, which includes a $25 million equity investment in the… Read More

#Business & Investment #News

#Abiologics #Artificial intelligence (AI) #Biologics #Generative AI #Synthetic biology

Abiologics launches with a new class of supranatural medicines

Abiologics, a Flagship Pioneering company, has launched to develop a new class of supranatural and programmable medicines called Synteins. Synteins are computationally-generated and synthesised with novel building blocks, potentially providing treatments across a wide range of diseases. Flagship has initially committed $50 million to advance the company’s platform and develop… Read More

#Business & Investment #News